A 1972 BMW 3.0 CSL, one of the most iconic homologation specials in the automaker’s history, is now up for auction via RM Sotheby’s. This Italian-market, second-series example has been meticulously ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

At the time of writing, the shares are down another 0.22% to $98.33 a piece. Although at one point earlier this morning, the shares were up 2.3% to $100.80 each. It's more bad news for investors after ...

This is the new Vauxhall Corsa GSE. It is a small car with big power that aims to channel the vibes of its ancestors and marks the carmaker’s return to small cars with big power. How big, you cry? Two ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

Opel and its badged-engineered British sister brand Vauxhall are rediscovering their hot hatch roots, but with a charging cable this time. The pair dropped their Corsa GSE today, along with a zero to ...

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

Biotechnology business CSL, which specialises in bloods, vaccines and plasma products, flagged a US$5 billion (AU$6.9 billion) write-down of its assets. The Melbourne-headquartered company also ...

CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...